AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05518331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: Avatrombopag, 40-60 mg (body weight \< 80 kg, 40 mg per day; body weight > 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
Study NCT04551053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered QD orally
Study NCT04551053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib will be administered BID orally
Study NCT05411133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotamig (ARB202)
Description: Cabotamig (ARB202), Atezolizumab
Study NCT03989167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Computer-based support tool for identification of patients with high levels of total cholesterol or LDL-C, at high risk of being affected by FH.
Study NCT06022029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONM-501
Description: Intratumoral injection
Study NCT06022029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous administration of 350 mg
Study NCT06432881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD SET Sensor
Description: All subjects are enrolled into this arm and will have Sp02 measurements obtained.
Study NCT06265038 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ReSpace TiCell Cage
Description: ReSpace TiCell Cages are anatomically shaped interbody spacer implants with curved contour. These implants intended to be inserted into the intervertebral disc space for intervertebral body fusion. The interbody spacers are designed to restore height and lordotic angle in the spine. The spacers have teeth on the endplate-engaging surfaces to provide stability, resist shear and rotational forces, and to help prevent migration of the spacer within the disc space. The open central cavity on them allows for placement of graft material allowing for subsequent bone growth through the interior of the devices.~ReSpace TiCell Cages are indicated for lumbar spine stabilization (between L.I.-S.I. segments). TLIF spine surgery will be combined with posterior fixation using pedicle screws and rods.
Study NCT04551053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ruxolitinib
Description: ruxolitinib will be administered BID orally
Study NCT04551053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered QD orally
Study NCT05756218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing diagnoses - taboo game
Description: Playing 7 weeks nursing diagnoses taboo cards
Study NCT06289062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
Study NCT06289062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
Study NCT06289062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
Study NCT06289062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: cone biopsy + pelvic lymphadenectomy or Cervical biopsy + pelvic lymphadenectomy
Study NCT06296251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Microcrystaline cellulose (MCC)
Study NCT06296251 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant derived phenolics
Description: Dietary supplement containing plant derived phenolics
Study NCT06136884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-252
Description: AO-252 will be administered oral tablets or capsules daily
Study NCT05923905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1006
Description: 30mg/day
Study NCT05923905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30mg/day
Study NCT06519110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib tablets
Description: In the first week, take Neratinib tablets 120mg orally, in the second week take Neratinib tablets 160mg orally, and from the third week until the end of treatment, take Nilotinib tablets 240mg orally (from Cycle 1 Day 15 until the end of treatment).
Study NCT05036720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP+Dads
Description: LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management.
Study NCT05036720 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LTP+Dads
Description: LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management.
Study NCT05036720 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LTP+ Optional mother component
Description: LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
Study NCT04336644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BodyGuardian Mini Plus
Description: The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
Study NCT04618393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMB-02
Description: EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.
Study NCT05151601 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 2 x sachets per day
Study NCT05151601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x sachets per day
Study NCT05387551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Dexcom G6 sensor, transmitter and supplies will be provided to family for use. Participants will wear G6 and have real-time glucose data throughout the study.
Study NCT06143111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flotrac Group
Description: Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
Study NCT06143111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioZ Group
Description: Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
Study NCT00498056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: DNA vaccine administered intramuscularly
Study NCT00498056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: Adenovirus vaccine administered intramuscularly
Study NCT00498056 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VRC-HIVDNA016-00-VP placebo
Description: DNA vaccine placebo administered intramuscularly
Study NCT00498056 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VRC-HIVADV014-00-VP placebo
Description: Adenovirus vaccine placebo administered intramuscularly
Study NCT04708964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
Study NCT04708964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
Study NCT05199727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LI-ESWT
Description: Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)
Study NCT05199727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 20Mg Oral Tablet
Description: Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
Study NCT03984201 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.
Study NCT03984201 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.
Study NCT03913546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Description: Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
Study NCT03913546 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham spinal manipulative therapy
Description: Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
Study NCT05270031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the eustachian tube
Description: Balloon dilation of the eustachian tube
Study NCT05288699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aliento
Description: Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
Study NCT06196203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: AK117 IV injection
Study NCT06196203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV injection
Study NCT06196203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine SC injection
Study NCT05633225 — intervention group
Intervention type: OTHER
Intervention: Submax exercise test on a bicycle ergometer
Description: To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard).
Study NCT06196203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine SC injection
Study NCT04791020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain topical + paracervical blockade
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade
Study NCT04791020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
Study NCT06577948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single vision spectacle lens
Description: Standard single vision spectacle lens
Study NCT06577948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P.A.U.S.E. spectacle lens 1
Description: P.A.U.S.E. spectacle lens 1
Study NCT06577948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P.A.U.S.E. spectacle lens 2
Description: P.A.U.S.E. spectacle lens 2
Study NCT06554899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician-led intervention to address fear of cancer recurrence (CIFeR)
Description: The intervention includes five components informed by theoretical models and existing interventions for FCR: 1) FCR normalization: reassurance that FCR is a common and normal phenomenon after treatment for cancer, 2) Providing prognostic information: asking patients whether they would like information about their risk of recurrence and, if yes,providing this information, 3) Providing education and take-home information on red-flag recurrence symptoms, 4) Brief advice on managing worry: distraction, meditation, mindfulness, reassurance, and links to online resources to manage FCR, and 5) referral to a psychologist if FCR is high (FCRI-SF >= 22), or if deemed helpful by the patient or clinician. Access will be provided to ConquerFear-Group delivered online by trained psychologists.
Study NCT06641258 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (Standard Procedure)
Description: Application in Control Group: After the theoretical lesson, the nurses in the control group determined and classified the pressure injuries in their patients using the  Braden Risk Assessment Scale, which has been accepted as valid and reliable. The nurses in the control group, who determined the pressure injuries using the scale, were given training on the determination and classification of pressure injuries using written material, the content of which was prepared by the researchers. After the training, the Satisfaction with the Training Method Survey was applied to the nurses. One week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied. After the completion of the application, volunteer nurses from the control group were subjected to pressure injury detection and classification with the deep learning model and trained with the mobile application.
Study NCT06641258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Application in the Experimental Group: After the theoretical course, the nurses in the experimental group detected and classified pressure injuries in their patients with the Deep Learning Model. In the experimental group, a mobile application developed by the researchers was installed on the phones of the nurses who detected pressure injuries using the deep learning model and training was applied. Thus, the nurses were provided with the patient's care and treatment according to the developed mobile application according to the pressure injury stage detected by the deep learning model. After the training, the Satisfaction Survey with the Training Method was applied to the nurses. 1 week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied
Study NCT06535893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TN
Description: Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
Study NCT06535893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TN-1
Description: Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
Study NCT06019832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty (TKA)
Description: Both study arms will undergo TKA
Study NCT06019832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stemmed Tibial Implant
Description: A stemmed tibial implant
Study NCT06019832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-stemmed tibial implant
Description: non-stemmed tibial implants
Study NCT05378763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Poziotinib tablets
Study NCT05378763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel IV infusion
Study NCT06420063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123/CD33 CART
Description: The intervention in this clinical trial involves a novel approach using CD22/123-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD33/123-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD33/123-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD33/123 CAR-T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses.
Study NCT06026332 — intervention group
Intervention type: DRUG
Intervention: ADSTILADRIN
Description: Non-interventional
Study NCT05363215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration
Study NCT05802875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RASMUS Resilience Training
Description: RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course.
Study NCT05802875 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation is a representative relaxation technique used in a wide scope of disorders. Developed by the American physician E.Jacobson in the late 1920s, it is based on the finding that anxiety states are usually accompanied by increased muscle tension, while in resting states the muscles are relaxed. By applying this technique, an individual learns how to relax several muscle groups in the body.~In the context of the current project, PMR is chosen as the active control condition because it is a broadly accepted and easy-to-implement relaxation exercise that can be offered as a (group) online course and does not include specific contents of RASMUS.
Study NCT05023876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM+respiratory Exercise
Description: Instrument assisted soft tissue mobilization
Study NCT04309500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized DAT Risk Disclosure Protocol
Description: Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
Study NCT05023876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Exercise
Description: Respiratory Exercise
Study NCT06643026 — intervention group
Intervention type: OTHER
Intervention: Food preference
Description: Evaluate the impact of chemotherapy on the dietary preferences of patients with digestive cancer using a dietary and quality-of-life questionnaire at the beginning, middle and end of the chemotherapy/immunotherapy treatment.